Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to test feasibility and efficacy of a dose reduced chemotherapy in elderly patients with newly diagnosed acute lymphoblastic leukemia. The regimen consists of induction phase I and II followed by cyclic consolidation cycles, reinduction and maintenance therapy

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johann Wolfgang Goethe University Hospital
• Treatments: 6-Mercaptopurine; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Idarubicin; Ifosfamide; Mercaptopurine; Methotrexate; Vincristine

Criteria

Inclusion Criteria:

• diagnosis of acute lymphoblastic leukemia (pro-B,common,pre-B,pre-T,Thy-,mature T, B-ALL)

• age > 65 years

• written informed consent

• Karnofsky > 50% (if not mainly caused by leukemia)

• laboratory at diagnosis or after supportive pre-treatment Creatinine < 2 mg/dl Uric Acid < 8 mg/dl Bilirubin < 1.5 mg/dl ALA, ASA,AP < 2.5 x ULN

Exclusion Criteria:

• severe second diseases (e.g. renal failure, cardiomyopathy etc., not caused by leukemia) that exclude treatment according to the protocol

• severe psychiatric illness or other circumstances which may compromise cooperation

• active second neoplasia

• clinical signs of life threatening infections or bleeding, uncontrollable prior to chemotherapy